George Clinical in Hong Kong
Hong Kong is George Clinical’s East Asia hub, overseeing our operations in Taiwan and Malaysia.
Hong Kong has a long history of international research with sophisticated infrastructure and resources across all phases. A small, densely populated area, Hong Kong world class hospitals offer excellent recruitment potential. Hong Kong has a long and impressive track record of conducting global clinical trials. Since the introduction of ICH GCP in 1996, Hong Kong has participated in over 1000 global clinical trials. Hong Kong has had a history of high quality clinical research output and plays a role of scientific leadership in Asia.
Hong Kong has excellent infrastructure in terms of transportation, work force and legal framework. Hong Kong has an outstanding healthcare system, as indicated by one of the lowest infant mortality rates and the longest life expectancy in the world. There are 41 public hospitals which provide 90% of the medical care in Hong Kong. Hong Kong is officially recognized by China State Food and Drug Administration for conducting clinical trials for drug registration purpose in mainland China in certain therapeutic areas. There is strong government support in clinical research, with the recent example being the set up of two Phase I centers at leading teaching hospitals in Hong Kong.
Hong Kong Wholesale Dealer Licence
George Clinical is pleased to announce the receipt of their Hong Kong Wholesale Dealer licence issued by the Department of Health on the 3rd April. This licence represents a significant step forward in George Clinical’s operations in Hong Kong, allowing them to apply for a Certificate of Clinical Trial on behalf of the sponsor and as such streamlining and speeding up the process of commencing a trial in Hong Kong.
“We are very pleased to announce the receipt of our Hong Kong Wholesale Dealer licence,” Evon Hui, Associate Director, East Asia said. “It is a strong endorsement of the work we are currently undertaking in Hong Kong and will allow us to build on our already robust operational delivery.”
George Clinical Hong Kong can now apply to import and/or export license(s) for Investigational Product shipments to and from the investigational sites after regulatory approval. Improving the start-up times by streamlining the process for George Clinical’s sponsors.
What are the benefits of conducting clinical trials in HK?
- Emerging market for clinical trials
- Advanced medical care
- Developed Infrastructure
- Strong presence of Academic institutions
- High Quality Investigators
What are the prevalent diseases in HK?
- Diabetes mellitus
- Heart Disease
Name and title
My name is Evon Hui and I am the Associate Business Director of Business Operations in East Asia
What countries constitute under East Asia and what is the estimated patient population in the region?
Currently, we have entities in East Asia across four countries, the hub is in Hong Kong and we have offices in Taiwan, South Korea, Malaysia. But we do have cover of clinical trials in different regions apart from these four countries and they are: Thailand; Vietnam; Singapore; and, Philippines. In terms of the populations, it’s estimated to be around 640 million people in these regions and definitely this provides a very large number of patient pools for conducting clinical trials.
What are the benefits of conducting a clinical trial in East Asia?
Just to mention again, it’s a wide population with wide diversity that offers a wide genetic diversity of population and on top of that, it offers a relatively lower cost comparing to the western countries like in Europe or in the US, it’s relatively more cost effective; and on top of that there are increasing number of enthusiastic researchers, very developed infrastructures in the hospitals that’s very good for conducting clinical trials.
How long has George Clinical had operations in East Asia and how many people are on the ground there?
We had started our operations back in 2009 and we offer various services that includes: project management; clinical operations; clinical monitoring; safety; and compliance. We have about six to ten personnel in each location that includes South Korea, Taiwan, Malaysia and Hong Kong. So total around 30 to 35 people on the ground.
What services does George Clinical offer sponsors in East Asia?
In East Asia, we do offer a wide variety of services, wide range of services – includes: project management; clinical monitoring; safety reporting; as well as, compliance.
Do sponsors get to pick and choose which countries in the region they wish to work in? And how does George Clinical help sponsors to decide which sites/countries are the most appropriate for their trial needs?
Whenever we receive a request for proposals, we would be evaluating the protocol together with our internal team. We might be conducting a high-level feasibility through our networks, through our scientific leaders, getting their opinions, which are the good sites and what’s the prevalence in each country and that way we would be proposing to our sponsors, this is the geomix that we think would be great for your study. And of course, we would be having a very tight communication with the sponsors and helping them to decide which countries would be the best for their studies and of course at the end it would be the sponsor’s call or decision to decide which countries would be best to conduct their study.
How can I learn more about the services that George Clinical offers in East Asia?
Please get in touch with us through www.georgeclinical.com for more information.
Hing Fong Road,
Kwai Fong, New Territories
Hong Kong S.A.R
|Number of Personnel:||13|
|In-country Services:||Project Management
|Official Language:||Cantonese (official) 89.5%, English (official) 3.5%, Putonghua (Mandarin) 1.4%, other Chinese dialects 4%, other 1.6%|
|Hospital Records Language:||English|
|Electronic Hospital Records:||Yes, stored centrally|
|Site Network:||41 public hospitals, which provide 90% of medical care in Hong Kon|
|GDP – per capita (US $):||$56,700|